



Imaxio signs a license agreement with the German Cancer Research Center (DKFZ)

Following a successful 2-year evaluation, Imaxio's pro-immunogenic technology IMX313P will be incorporated in a DKFZ' vaccine candidate targeting human papillomavirus (HPV)

Lyon, France – April 03, 2017 – Imaxio, a biotech company specializing in immunology announces today that it has signed a license agreement with the world-renowned German Cancer Research Center (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed.

It follows a 2-year evaluation of Imaxio's IMX313P pro-immunogenic technology by DKFZ under a license option agreement. This evaluation has proven the ability of IMX313P to enhance the efficacy of a DKFZ' vaccine candidate indicated in the prevention of human papillomavirus (HPV) infections, a virus that can lead to cervical cancers. DKFZ has therefore decided to exercise its option right, and to move forward in the development of this IMX313P-based vaccine candidate.

"This deal with a renowned academic institution such as DKFZ is a real acknowledgement of our vaccine technology," said Alexandre Le Vert, chief executive officer of Imaxio. "It strengthens the confidence we have in our early-clinical stage pipeline of vaccines based on IMX313P."

"Being provided with IMX313P increases the probability of our HPV vaccine candidate to reach the market," added Professor Martin Müller, director of the Research Group Tumorvirus-specific Vaccination Strategies at DKFZ. "We are now ready to move forward with the regulatory development of our IMX313P-based HPV vaccine candidate."

According to World Health Organization estimates, cervical cancer affects approximately 450.000 women worldwide each year.

About Imaxio

Imaxio is a small biotechnology company focused on immunology, with products ranging from commercial stage to clinical and preclinical R&D stages.

Imaxio commercializes in France a human vaccine indicated for the prevention of an infectious occupational disease, called Spirolept®.

Its clinical-stage R&D pipeline is focused on vaccines for infectious diseases (malaria, influenza, etc.) and an immunotherapy in oncology.



It is based on the IMX313P technology, an antigen re-engineering platform developed by Imaxio to improve the efficacy of vaccines, which is protected by a strong portfolio of 4 patent families.

Imaxio partners with national and international renowned research structures, including the Jenner Institute at Oxford University (UK), the German Cancer Research Centre (DKFZ), Inserm (France), CNRS (France) and the Léon Bérard Cancer Centre (Lyon, France).

Based in Lyon (France), more than half of the twenty Imaxio employees is dedicated to R&D activities. In 2016, its turnover reached EUR 2.2 million.

For further information: www.imaxio.com

About the German Cancer Research Center

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and the treatment of cancer patients more successful.

The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic.

In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients.

DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

For further information: www.dkfz.de